OncLive
Jay Yang, M.D., leader of the Hematology Oncology Multidisciplinary Team at Karmanos Cancer Institute explains that most mantle cell lymphoma (MCL) patients will need treatment although there is not a true standard of care for the disease.
Read the full article here.